ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2459
0,00%
Bitcoin
67.644,31
0,24%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Acer Therapeutics Com USD0.01 (OPXA)

  7. Acer Therapeutics Com USD0.01 (OPXA) Notícias

OPXA

Acer Therapeutics Com USD0.01 (OPXA)

Acer Therapeutics Com USD0.01
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OPXA
DataHoraFonteTítuloCódigoCompanhia
06/10/201717:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPXAAcer Therapeutics Com USD0.01
06/10/201717:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:OPXAAcer Therapeutics Com USD0.01
05/10/201709:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPXAAcer Therapeutics Com USD0.01
29/09/201717:51Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:OPXAAcer Therapeutics Com USD0.01
01/09/201708:31Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OPXAAcer Therapeutics Com USD0.01
14/08/201708:34Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPXAAcer Therapeutics Com USD0.01
11/08/201707:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:OPXAAcer Therapeutics Com USD0.01
11/08/201707:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OPXAAcer Therapeutics Com USD0.01
08/08/201718:17Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:OPXAAcer Therapeutics Com USD0.01
04/08/201717:10Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:OPXAAcer Therapeutics Com USD0.01
19/07/201718:26Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:OPXAAcer Therapeutics Com USD0.01
03/07/201707:13Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:OPXAAcer Therapeutics Com USD0.01
28/03/201717:06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:OPXAAcer Therapeutics Com USD0.01
08/12/201615:17Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:OPXAAcer Therapeutics Com USD0.01
11/08/201618:20Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:OPXAAcer Therapeutics Com USD0.01
11/04/201607:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:OPXAAcer Therapeutics Com USD0.01
25/03/201617:27Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:OPXAAcer Therapeutics Com USD0.01
24/03/201601:37InvestorsHub NewsWireOPEXA THERAPEUTICS - RESTRUCTURING SHARPENS FOCUS ON TCELNA DATANASDAQ:OPXAAcer Therapeutics Com USD0.01
18/03/201617:06Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:OPXAAcer Therapeutics Com USD0.01
05/02/201619:06Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OPXAAcer Therapeutics Com USD0.01
17/11/201511:00Business WireOpexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to WatchNASDAQ:OPXAAcer Therapeutics Com USD0.01
10/11/201519:05Business WireOpexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO) ProgramNASDAQ:OPXAAcer Therapeutics Com USD0.01
10/11/201519:01Business WireOpexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate UpdateNASDAQ:OPXAAcer Therapeutics Com USD0.01
06/11/201511:30Business WireOpexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial ResultsNASDAQ:OPXAAcer Therapeutics Com USD0.01
19/10/201510:11Business WireOpexa Therapeutics to Host Analyst and Investor Event on November 10 in New YorkNASDAQ:OPXAAcer Therapeutics Com USD0.01
15/10/201509:00Business WireOpexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing RequirementNASDAQ:OPXAAcer Therapeutics Com USD0.01
13/10/201508:00Business WireOpexa Therapeutics to Present at BIO Investor ForumNASDAQ:OPXAAcer Therapeutics Com USD0.01
06/10/201508:00Business WireOpexa Announces Granting of New T-cell Patents Covering Tcelna®; Patent Estate Increases to 160 Issued PatentsNASDAQ:OPXAAcer Therapeutics Com USD0.01
28/09/201508:00Business WireOpexa Announces Reverse Stock SplitNASDAQ:OPXAAcer Therapeutics Com USD0.01
01/09/201507:00Business WireOpexa Secures Private Funding for its NMO Orphan Development Program, Including Planned Phase I/II Clinical StudyNASDAQ:OPXAAcer Therapeutics Com USD0.01
 Apresentando as notícias mais relevantes sobre:NASDAQ:OPXA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
CIEL3
CIELO ON
BOV
PRIO3
PETRORIO ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
TECN3
TECHNOS ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados